TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.080
-0.010 (-0.92%)
At close: Dec 5, 2025, 4:00 PM EST
1.090
+0.010 (0.94%)
After-hours: Dec 5, 2025, 7:55 PM EST
TScan Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 8.42 | 2.82 | 21.05 | 13.54 | 10.14 | 1.09 | |
| Revenue Growth (YoY) | -10.03% | -86.62% | 55.52% | 33.47% | 834.65% | - | |
| Cost of Revenue | 20.96 | 4.85 | 2.88 | 59.82 | 44.95 | 20.58 | |
| Gross Profit | -12.54 | -2.03 | 18.17 | -46.28 | -34.81 | -19.49 | |
| Selling, General & Admin | 33.63 | 30.29 | 26.35 | 20.35 | 13.83 | 6.74 | |
| Research & Development | 102.5 | 102.5 | 85.28 | - | - | - | |
| Operating Expenses | 136.13 | 132.79 | 111.63 | 20.35 | 13.83 | 6.74 | |
| Operating Income | -148.67 | -134.82 | -93.46 | -66.64 | -48.64 | -26.23 | |
| Interest Expense | -2.85 | -3.65 | -3.76 | -1.18 | - | - | |
| Interest & Investment Income | 10.01 | 12.07 | 8 | 1.59 | 0.02 | 0.11 | |
| EBT Excluding Unusual Items | -141.51 | -126.41 | -89.22 | -66.22 | -48.63 | -26.13 | |
| Other Unusual Items | -1.09 | -1.09 | - | - | - | - | |
| Pretax Income | -142.6 | -127.5 | -89.22 | -66.22 | -48.63 | -26.13 | |
| Net Income | -142.6 | -127.5 | -89.22 | -66.22 | -48.63 | -26.13 | |
| Net Income to Common | -142.6 | -127.5 | -89.22 | -66.22 | -48.63 | -26.13 | |
| Shares Outstanding (Basic) | 57 | 57 | 48 | 24 | 12 | 1 | |
| Shares Outstanding (Diluted) | 57 | 57 | 48 | 24 | 12 | 1 | |
| Shares Change (YoY) | 6.36% | 18.32% | 98.89% | 106.20% | 1173.20% | 137.86% | |
| EPS (Basic) | -2.51 | -2.25 | -1.87 | -2.75 | -4.17 | -28.52 | |
| EPS (Diluted) | -2.51 | -2.25 | -1.87 | -2.75 | -4.17 | -28.52 | |
| Free Cash Flow | -135.85 | -114.65 | -64.5 | -70.73 | -58.62 | -7.26 | |
| Free Cash Flow Per Share | -2.39 | -2.03 | -1.35 | -2.94 | -5.03 | -7.93 | |
| Gross Margin | -148.85% | -72.09% | 86.34% | - | - | - | |
| Operating Margin | -1765.01% | -4787.68% | -444.00% | -492.32% | -479.65% | -2417.79% | |
| Profit Margin | -1692.96% | -4527.66% | -423.86% | -489.26% | -479.49% | -2408.02% | |
| Free Cash Flow Margin | -1612.88% | -4071.27% | -306.45% | -522.56% | -578.03% | -669.22% | |
| EBITDA | -145.81 | -130.71 | -88.1 | -61.5 | -45.31 | -25 | |
| D&A For EBITDA | 2.85 | 4.11 | 5.36 | 5.14 | 3.33 | 1.23 | |
| EBIT | -148.67 | -134.82 | -93.46 | -66.64 | -48.64 | -26.23 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.